Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

This registry study is collecting real-world data on how newly diagnosed multiple myeloma patients are treated when their care follows a structured clinical pathway. It aims to understand how well these pathways are being used and whether they improve outcomes, including by tracking a measure of treatment response called MRD (minimal residual disease). **You may be eligible if...** - You have been newly diagnosed with multiple myeloma - You are 18 years or older - You received your diagnosis on or after the launch of the clinical pathway program in the participating network - You have continued receiving care at a participating practice for at least 90 days after diagnosis **You may NOT be eligible if...** - You have another active cancer at the same time (with some exceptions for non-melanoma skin cancers and in situ cancers) - You have been treated for another cancer in the past 3 years - Your myeloma is an IgD or IgE subtype (very rare) - You transferred your care to a non-participating clinic within the first 90 days after diagnosis Talk to your doctor to see if this trial is right for you.